Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Page 23 of 30
Mar 18, 2026Johnson & Johnson's newly approved pill represents a milestone in psoriasis treatment, providing patients a daily oral alternative to current injectable therapies. This approval has the potential to disrupt the existing treatment landscape and address patient preferences for less invasive medication options.
Mar 18, 2026Johnson & Johnson continues to dominate the pharmaceutical industry by revenue, underscoring its robust portfolio and market presence. Meanwhile, Eli Lilly's recent surge as the leader in obesity treatment highlights shifting dynamics in pharma sectors, attracting substantial investor attention.
Mar 17, 2026The partnership between Astellas and CytomX began in 2020 with an $80 million upfront investment to develop masked antibody therapies targeting cancer. Recent developments highlight strategic industry shifts despite scientific progress.
Mar 13, 2026The rare disease market is poised for remarkable expansion driven primarily by innovative small molecule drugs. Insights from Evaluate underscore the increasing value and potential of these therapies in addressing orphan diseases, shaping the future biopharma landscape.
Mar 13, 2026In a notable development in the biopharma sector, Novo Nordisk and Hims & Hers settled their legal dispute over GLP-1 drugs and agreed on a collaborative partnership. This move underscores the interdependence of traditional pharmaceutical giants and new entrants in the evolving obesity and diabetes treatment landscape.
Mar 12, 2026The biopharmaceutical industry has faced a challenging employment landscape since 2022, but recent data reveal encouraging trends in hiring and workforce stability. February 2026 marked the first month with a year-over-year increase in average job postings on BioSpace, alongside a decrease in employee layoffs among biopharma companies.
Mar 10, 2026Analysts have forecasted a rapid expansion in the cell and gene therapy manufacturing market over the next decade. This growth reflects heightened production demand as more therapies gain regulatory approval and enter the clinic. The rapidly evolving biotechnology sector is expected to see significant transformation, with implications for manufacturers, investors, and the broader health industry.
Mar 10, 2026With upfront costs long identified as a major barrier to advancing continuous manufacturing processes in the pharmaceutical industry, the nonprofit API Innovation Center steps forward with strategies to facilitate investment and modernization. This report explores the challenges faced, the center's proposed solutions, and the broader implications for the drug manufacturing sector in the U.S.
Mar 10, 2026Vertex Pharmaceuticals recently reported late-stage clinical trial results revealing that their drug candidate successfully reduced a pivotal marker of IgA nephropathy, a chronic kidney disease, by approximately 50%. This achievement may mark a critical milestone in the treatment of this rare condition and reflects strategic efforts following Vertex’s substantial acquisition valued at $4.9 billion.
Mar 9, 2026In a significant move within the rare disease market, Italian pharmaceutical company Alfasigma has acquired the worldwide rights to linerixibat, a drug developed by GlaxoSmithKline (GSK) targeted at primary biliary cholangitis (PBC), a rare autoimmune liver condition. This deal comes at a critical time as linerixibat approaches an FDA decision, potentially reshaping treatment options for PBC patients worldwide.
Mar 6, 2026Novo Nordisk's widely prescribed GLP-1 receptor agonists, Wegovy and Ozempic, currently command high prices in the market. However, emerging analyses propose that their generic counterparts could be manufactured at a fraction of the cost, pointing towards potential shifts in pricing dynamics and patient accessibility.
Mar 6, 2026In a major industry development, Servier has agreed to acquire Day One Biopharmaceuticals, renowned for its pediatric cancer drug Ojemda. This acquisition reflects a strategic investment to enhance Servier's pediatric brain tumor portfolio and advance treatments for childhood glioma.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.